1-[(2,4-dichlorophenyl)methyl]-5-[2-oxo-2-[4-(pyridin-2-ylmethyl)piperazin-1-yl]ethyl]pyrrolidin-2-one
C23H26Cl2N4O2 — CID 175838030
Data last refreshed: (MolForge compound catalog, from PubChem)
About 1-[(2,4-dichlorophenyl)methyl]-5-[2-oxo-2-[4-(pyridin-2-ylmethyl)piperazin-1-yl]ethyl]pyrrolidin-2-one
1-[(2,4-dichlorophenyl)methyl]-5-[2-oxo-2-[4-(pyridin-2-ylmethyl)piperazin-1-yl]ethyl]pyrrolidin-2-one (PubChem CID 175838030) has the molecular formula C23H26Cl2N4O2 and a molecular weight of 461.39 g/mol. Its IUPAC name is 1-[(2,4-dichlorophenyl)methyl]-5-[2-oxo-2-[4-(pyridin-2-ylmethyl)piperazin-1-yl]ethyl]pyrrolidin-2-one.
Molecular Properties
| Compound Name | 1-[(2,4-dichlorophenyl)methyl]-5-[2-oxo-2-[4-(pyridin-2-ylmethyl)piperazin-1-yl]ethyl]pyrrolidin-2-one |
|---|---|
| PubChem CID | 175838030 |
| Molecular Formula | C23H26Cl2N4O2 |
| Molecular Weight | 461.39 g/mol |
| Exact Mass | 460.14 |
| IUPAC Name | 1-[(2,4-dichlorophenyl)methyl]-5-[2-oxo-2-[4-(pyridin-2-ylmethyl)piperazin-1-yl]ethyl]pyrrolidin-2-one |
| SMILES | O=C(CC1CCC(=O)N1Cc1ccc(Cl)cc1Cl)N1CCN(Cc2ccccn2)CC1 |
| InChI | InChI=1S/C23H26Cl2N4O2/c24-18-5-4-17(21(25)13-18)15-29-20(6-7-22(29)30)14-23(31)28-11-9-27(10-12-28)16-19-3-1-2-8-26-19/h1-5,8,13,20H,6-7,9-12,14-16H2 |
| InChIKey | SKQRTXODEOGPEG-UHFFFAOYSA-N |
| XLogP | 3.61 |
| TPSA | 56.75 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 4 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 31 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 461.39 |
| LogP ≤ 5 | 3.61 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 4 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 175838030 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.